Fusion Antibodies (LON:FAB) Stock Price Down 2.6% – Here’s What Happened

Fusion Antibodies plc (LON:FAB)’s share price fell 2.6% during mid-day trading on Wednesday . The company traded as low as GBX 12.17 and last traded at GBX 12.17. 56,650 shares changed hands during trading, a decline of 88% from the average session volume of 464,675 shares. The stock had previously closed at GBX 12.50.

Fusion Antibodies Price Performance

The company has a debt-to-equity ratio of 92.42, a quick ratio of 2.36 and a current ratio of 1.80. The firm has a market cap of £15.07 million, a price-to-earnings ratio of -8.03 and a beta of 1.22. The stock’s 50 day simple moving average is GBX 13.35 and its 200-day simple moving average is GBX 13.76.

About Fusion Antibodies

Fusion is a Belfast based contract research organisation (“CRO”) providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company’s ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion’s proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials.